Seres therapeutics announces new translational biomarker results from ser-155 phase 1b clinical study and provides corporate updates

New ser-155 phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-hsct) recipients demonstrate that ser-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of seres' live biotherapeutics to target inflammatory and immune diseases
MCRB Ratings Summary
MCRB Quant Ranking